3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
10
Completed
7
Unknown
4
Not yet recruiting
3
Terminated
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphatic Metastasis
1
Esophageal Squamous Cell Carcinoma
1
Interventions
camrelizumab
2
Radiotherapy
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
tislelizumab
1
pembrolizumab
1
nimotuzumab
1
atropine sulfate-diphenoxylate hydrochloride drug combination
1
Omeprazole
1
Loperamide
1
High-Energy Shock Waves
1
Gastroscopy
1
Esophagectomy
1
Drug Therapy
1
Dexamethasone
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Esophageal Squamous Cell Carcinoma
×
tislelizumab
×
Clear all
NCT06303583
2024-03-12
CRIS
Zhejiang Cancer Hospital
Phase 1/2
Enrolling by invitation
30 enrolled